Fasting-mimicking diet with chemo-immunotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a special low-calorie diet (called a fasting-mimicking diet) to standard chemotherapy and immunotherapy can help treat triple-negative breast cancer before surgery. It aims to see if this combination makes the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with triple-negative or near-triple-negative breast cancer, and the tumor is at least 2 cm or has spread to lymph nodes.
- You have not had any prior cancer treatment like chemotherapy, radiation, or targeted therapy.
- You are able to follow a special diet plan and all study procedures.
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You do not have diabetes that requires medication (except metformin), and you have not lost a lot of weight unintentionally recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds a fasting-mimicking diet to standard chemotherapy before surgery for a specific type of breast cancer. The diet may help make the chemotherapy work better while reducing side effects.
This study tests if a special diet that mimics fasting can help reduce side effects from hormone therapy (aromatase inhibitors) in women with breast cancer. The diet is a low-calorie meal plan designed to lower cholesterol and improve well-being.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.